CDK4 and adenocarcinoma: The previous study has shown that adenocarcinoma cell lines are more sensitive to CDK4 than squamous cancer cell lines (10).Unfortunately, recent clinical trials of CDK4/6i as single agents in non-small cell lung cancer (NSCLC) have not achieved satisfactory results (11–14).